About
A creative scientist with extensive drug discovery and preclinical development experience…
Experience
-
-
-
-
-
-
-
-
-
Education
Other similar profiles
Explore more posts
-
Cade Hildreth - BioInformant
Nucleus Biologics Launches QuickStart Media™: A Suite of Optimized Media Formulations That Provide a Head Start on Your Therapy Optimization - https://lnkd.in/gYKezEBS Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media and buffers for the cell and gene therapy industry, announces the launch of a novel platform to expedite the formulation and manufacture of custom media. This platform, called QuickStart Media™, is a groundbreaking addition to its comprehensive line of cell culture products and solutions and further demonstrates Nucleus Biologics’ expertise and dedication to the delivery of custom cell culture media, buffers, reagents, and services simpler and faster. As the name implies, QuickStart Media was developed to provide scientists with a head start in the development of a high performing, custom media. The formulations that carry the QuickStart Media brand have all been developed for high performance for specific cell types or functions but allow full customization of components and final packaging enabling researchers to tailor their product to fit their exact process or critical quality attributes (CQAs). This offering stands alone in the cell culture market by providing researchers with both the convenience of off-the-shelf and the flexibility of custom media. This process offers transparency through licensing that can both enhance performance and supply chain consistency. “Nucleus Biologics is committed to empowering scientists with the tools they need to drive innovation and discovery,” said David Sheehan, President and CEO of Nucleus Biologics. “QuickStart Media represents the first platform of proven formulations that can be optimized and licensed to allow unprecedented transparency. This flexibility not only accelerates the research process, but also speeds the time for therapy developers to get into the clinic. As a critical component of a therapy, the industry needs to shift its thinking and allow scientists to know what is in their media and optimize their therapy. Ultimately, this is about faster cures.” #cellculture #celltherapy #genetherapy #custommedia David De Leonardis Brad Taylor
2 Comments -
Hung Trinh
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™ WARREN, N.J., May 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024. "We are excited to be one step closer to bringing an approved therapy to patients with AADC deficiency in the United States," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. "The data collected to date continue to support the transformative benefit of Upstaza, this highly innovative gene therapy directly infused into the brain." About Upstaza™ (eladocagene exuparvovec) Upstaza is a one-time gene replacement therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L–amino acid decarboxylase (AADC) deficiency with a severe phenotype. It is a recombinant adeno-associated virus serotype 2 (AAV2) https://lnkd.in/e5EvQp7D
-
LucidQuest
LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Genentech ends SHP2 deal with Relay Therapeutics after other pharma exits: Roche’s Genentech is scrapping a collaboration and license agreement with Relay Therapeutics surrounding the biotech’s clinical-stage oral SHP2 inhibitor. It’s the latest pharmaceutical company to renege on a SHP2 partnership in oncology. Bristol Myers Squibb departed a pact with BridgeBio earlier this year, AbbVie did the same with Jacobio Pharma in 2023 and Sanofi left Revolution Medicines in 2022. Merck, meanwhile, continues to have a SHP2 deal in place with Taiho and Astex. Genentech “elected to terminate the agreement without cause,” Cambridge, MA-based Relay disclosed in a Tuesday post-market SEC filing. As part of their 2020 deal, Genentech had assumed development of the oral small molecule, dubbed GDC-1971/RLY-1971 or migoprotafib. The decision was “not based on any emerging clinical safety concerns,” a Genentech spokesperson said in an emailed statement to Endpoints News. The drug went through a monotherapy study a few years ago and is in a couple of Phase 1 trials in combination with other drugs. The pair had broad ambitions for the SHP2 inhibitor across multiple solid tumor types, including as a combination partner for Genentech’s KRAS G12C candidate known as GDC-6036 or divarasib. “Genentech is committed to ensuring that patients being treated with GDC-1971 in clinical trials continue to have access,” the Genentech spokesperson said. “All patients enrolled in a trial involving GDC-1971 or combinations thereof will continue to receive study treatment as long as they meet study criteria and they and their physician agree to continue.” Relay received $75 million upfront to kick off the collaboration in late 2020. Genentech has paid about another $45 million in biobucks and R&D reimbursements since then, according to Relay’s SEC paperwork on Tuesday. Under the original pact, Relay could have received up to $695 million in milestone payments. Roche, the parent of Genentech, has broadly fine-tuned its pipeline in the past year. Genentech itself broke off a T cell therapy tie-up with Adaptimmune earlier this year, and is also reducing about 3% of its workforce, the company told Endpoints in April. “We’ve taken out 20% of our molecules that have a lower likelihood to succeed, and we’ve added new ones through partnering,” Roche CEO Thomas Schinecker said on a first-quarter earnings call with the media in April. It’s part of normal business to prioritize and “constantly reallocate,” he added. Relay doesn’t plan to make any workforce changes as a result of the axed deal, given Genentech was the one responsible for the experimental medicine’s development, a spokesperson for the biotech told Endpoints. #lucidquest #genetherapy #celltherapy
-
Where Tech Meets Bio (Substack Newsletter)
Weekly Tech Bio Highlights: • Building Foundation Models for Cancer Biology: NOETIK is developing self-supervised world models that learn cancer biology from primary data to discover new therapeutic insights, co-founded by Ron Alfa, MD, PhD. • Meet nach0: a New General Purpose LLM for Chemical and Biomedical Applications: Insilico Medicine and NVIDIA introduced nach0, a large language model for biological and chemical tasks, detailed in the Chemical Science Journal. Alex Zhavoronkov, CEO of Insilico Medicine, highlights the model's capabilities in integrating diverse datasets for biological and chemical applications. • Owkin, co-founded by Thomas Clozel Unveils AI-Driven Oncology and Immunology Pipeline: Owkin has unveiled an AI-driven pipeline, featuring OKN4395, a dual EP2/4 antagonist, set for Phase 1 trials in 2025. • Novel Cell Analytics Technology: Cytomos will present its advanced cell analytics technology, Celledonia™, at ISCT 2024, enhancing cell and gene therapy processes. • Quantum Computing in Biopharma: - Key companies and initiatives; - Quantum advantage in biopharma; - Challenges and future outlook. • New Discovery Potentially to Re-write Biology Textbooks: Researchers have discovered a unique bacterial enzyme that creates new genes by reading RNA templates and converting them into DNA, challenging the traditional understanding of genetic information flow. For a more detailed overview and more, check out the full article: https://lnkd.in/dxPJ5MCe
-
David Luci
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), a clinical stage #biopharmaceutical company focused on developing new #antibiotics for difficult-to-treat #bacterial infections, has announced a conference call to discuss its second quarter 2024 financial results. The call is scheduled for August 9, 2024, at 8:00 am ET, before the U.S. financial markets open. The company's President and CEO, David Luci, along with CFO Robert Shawah, will host the call to present the #financial results and provide a business update. #Investors and interested parties can join the call using the provided toll-free number for U.S. participants or international access numbers. https://lnkd.in/esMuCywW #nasdaq #acxp #antibiotics #acurx Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) David Luci
-
Lynx.MD
🌐 The Lynx.MD team is heading to San Diego for DIA 2024. Drug discovery is a complex, lengthy process. DIA brings together the life sciences community to discuss innovations accelerating advancements, bringing therapies to care faster. Reach out to the Lynx.MD team, including Collin Labar, on LinkedIn to learn more about how our partners are using Lynx.MD’s rich structured and unstructured data sets to find insights addressing medical affairs and market access. See you at #DIA2024! 🌟 #Data #Research
-
The McDonnell Genome Institute, WashU Medicine
Researchers from Amgen's deCODE genetics have corrected their 2023 Nature paper, reversing their previous findings. Initially, Olink's Explore 3072 platform was deemed more precise than Standard BioTools' SomaScan v4. However, the corrected study now shows SomaScan as the more precise platform due to a data misinterpretation involving sample handling. This development highlights the intense competition and ongoing advancements in proteomics technologies, with significant implications for large-scale studies measuring plasma proteins. What are your thoughts on this correction and its impact on the field? Share your insights! https://lnkd.in/gc3Q_ctu SomaLogic #proteomics #genomics #medicine #technology
-
uBriGene Biosciences Inc.
🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Stephen Betz in United States
-
Stephen Betz
-
Stephen Betz
Sports Management Major at Syracuse University |NCAA Division 1 National Champion
-
Stephen Betz
Mutual Fund Administrator
-
Stephen Betz
Insurance and Risk Manager, Dubner Landscaping & Construction
63 others named Stephen Betz in United States are on LinkedIn
See others named Stephen Betz